We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

102 hedge funds and large institutions have $102M invested in Zentalis Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

604% more call options, than puts

Call options by funds: $971K | Put options by funds: $138K

170% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 10

85% more capital invested

Capital invested by funds: $54.9M → $102M (+$46.8M)

19% more funds holding

Funds holding: 86 → 102 (+16)

5.23% more ownership

Funds ownership: 56.18% → 61.41% (+5.2%)

7% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 28

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
27
Increased
30
Reduced
28
Closed
10
Calls
$971K
Puts
$138K
Net Calls
+$833K
Net Calls Change
+$806K

Top Buyers

1
SCM
Squadron Capital Management
Illinois
+$9.38M
2
Two Sigma Investments
Two Sigma Investments
New York
+$3.84M
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.6M
4
Millennium Management
Millennium Management
New York
+$1.59M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.45M

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$2.44M
2
GCP
GSA Capital Partners
United Kingdom
-$1.42M
3
UBS Group
UBS Group
Switzerland
-$1.34M
4
Morgan Stanley
Morgan Stanley
New York
-$1.17M
5
WP
Woodline Partners
California
-$683K
Name Holding Trade Value Shares
Change 		Change in
Stake
5VM
1
5AM Venture Management
California
$9.24M – – –
SCM
2
Squadron Capital Management
Illinois
$8.5M +$9.38M +3,631,000 New
Two Sigma Investments
3
Two Sigma Investments
New York
$6.92M +$3.84M +1,485,112 +101%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$6.66M -$2.69K -1,042 -0%
VCM
5
Vanguard Capital Management
Pennsylvania
$5.41M +$5.97M +2,310,707 New
Renaissance Technologies
6
Renaissance Technologies
New York
$4.54M -$2.44M -945,600 -33%
Citadel Advisors
7
Citadel Advisors
Florida
$4.05M -$600K -232,172 -12%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$3.47M -$455K -176,280 -11%
OM
9
Opaleye Management
Massachusetts
$3.31M +$30.3K +11,750 +0.8%
DC
10
Decheng Capital
California
$3.1M – – –
Millennium Management
11
Millennium Management
New York
$3.02M +$1.59M +616,693 +92%
BlackRock
12
BlackRock
New York
$2.97M +$51.3K +19,869 +2%
II
13
Ishara Investments
California
$2.88M -$232K -90,000 -7%
Bank of America
14
Bank of America
North Carolina
$2.65M -$607K -234,960 -17%
Primecap Management
15
Primecap Management
California
$2.24M – – –
P
16
Pfizer
New York
$2M – – –
Connor, Clark & Lunn Investment Management (CC&L)
17
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.85M +$12.8K +4,946 +0.6%
Qube Research & Technologies (QRT)
18
Qube Research & Technologies (QRT)
United Kingdom
$1.49M +$1.6M +619,645 +3,547%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.45M +$82.5K +31,931 +5%
GCP
20
GSA Capital Partners
United Kingdom
$1.45M -$1.42M -549,166 -47%
AC
21
Almitas Capital
California
$1.43M – – –
Barclays
22
Barclays
United Kingdom
$1.38M +$58.8K +22,774 +4%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$1.34M +$1.45M +560,914 +5,423%
Jane Street
24
Jane Street
New York
$1.15M +$44.3K +17,164 +4%
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$1.1M +$134K +52,071 +12%
1
2 3 4 5

ZNTL Hedge Fund Activity: Q1 2026 in Review

102 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2026, worth a combined $102M — up 85% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ZNTL positions and 10 closed out — a net gain of 17 holders — while 30 added to existing stakes and 28 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $9.38M. The largest seller was Renaissance Technologies, cutting an estimated $2.44M.

  • 102 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2026, up from 86 in Q4 2025.
  • Funds reported $102M of Zentalis Pharmaceuticals stock for Q1 2026, up 85% quarter-over-quarter.
  • 27 funds opened new Zentalis Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q1 2026 was Squadron Capital Management, an estimated $9.38M added.
  • The largest Zentalis Pharmaceuticals seller in Q1 2026 was Renaissance Technologies, an estimated $2.44M sold.

Based on aggregated 13F filings for Q1 2026.